Targets › S100A9
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Dec 2027.
S100A9 is a calcium- and zinc-binding protein which plays a prominent role in the regulation of inflammatory processes and immune response. It can induce neutrophil chemotaxis, adhesion, can increase the bactericidal activity of neutrophils by promoting phagocytosis via activation of SYK, PI3K/AKT, and ERK1/2 and can induce degranulation of neutrophils by a MAPK-dependent mechanism. (UniProt, P06702)
Open in Phaseline: the race on S100A9, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Stichting Hemato-Oncologie voor Volwassenen Nederland | Tasquinimod S100A9 inhibitor | S100A9 | Phase 1 | Myelofibrosis | Dec 2027 |
Myelofibrosis (1)
small molecule (1)
Stichting Hemato-Oncologie voor Volwassenen Nederland (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.